文献速递重症综合管理与镇静镇痛复苏、休克与脓毒症

重症监护病房中的血小板减少症:诊断与管理

Thrombocytopenia in the intensive care unit: diagnosis and management.
PubMed 文献 · Ann Intensive Care · 2025-02-22
一句话结论重症患者血小板减少常见、病因多样且与预后恶化相关;预防性输注阈值多源自血液科稳定患者,ICU 亟需介入试验。

本叙述性综述描述重症患者血小板减少的流行病学与病因、出血风险评估,并更新血小板输注指征。经典定义为血小板绝对值低于 150 × 109/L,也可用较基线相对下降(典型范围 >30% 至 >50%)而绝对值仍高于 150 × 109/L 来定义。血小板减少是重症患者不良结局的独立决定因素,并与出血并发症发生率增加相关,但出血风险还受其他因素影响。血小板输注是预防或治疗出血的主要支持治疗;由于缺乏比较 ICU 预防性输注不同血小板计数阈值的随机对照试验,预防性输注策略主要来自血液科稳定患者的研究,侵入操作前阈值证据级别也低;严重出血治疗阈值多为经验性,范围 50 至 100 × 109/L;严重创伤相关出血的大剂量输血方案包含早期积极血小板输注。

要点

  • 经典定义:血小板绝对计数低于 150 × 109/L;相对定义:较基线下降 >30% 至 >50% 而仍高于 150 × 109/L。
  • 血小板减少是重症患者不良结局的独立决定因素,并与出血并发症发生率增加相关,但常难以解释。
  • ICU 缺乏比较预防性血小板输注不同阈值的随机对照试验,预防策略主要源自血液科稳定患者研究。
  • 严重出血时血小板输注指征多为经验性,血小板计数阈值范围 50 至 100 × 109/L。
  • 严重创伤相关出血的大剂量输血方案包含早期积极血小板输注。

适用人群与场景

  • 重症患者(ICU 人群),包括伴或不伴出血并发症者。

诊断标准与关键阈值

  • 经典定义:血小板绝对计数低于 150 × 109/L。
  • 相对定义:血小板计数较基线下降 >30% 至 >50%(典型范围),但绝对值仍高于 150 × 109/L。

处置流程与药物剂量

  • 血小板输注是血小板减少的主要支持治疗,用于预防或治疗出血。
  • 预防性血小板输注策略主要来自血液科稳定患者的研究,因 ICU 缺乏比较不同血小板计数阈值的随机对照试验。
  • 侵入操作前血小板输注阈值仍基于低级别证据。
  • 严重出血的血小板输注指征多为经验性,血小板计数阈值范围 50 至 100 × 109/L。
  • 严重创伤相关出血的大剂量输血方案包含早期积极血小板输注。

红旗征与不能漏的情况

  • 血小板减少与出血并发症发生率增加相关;出血风险还受其他因素影响,难以在最低血小板计数与潜在不良事件之间建立明确联系。

研究设计与关键结果

  • 叙述性综述:血小板减少在重症患者中常见,病因取决于基础疾病和临床情境,可为多种机制所致。
  • 血小板减少是重症患者不良结局的独立决定因素,常难以解释。
  • 血小板减少与出血并发症发生率增加相关,但其他因素也参与出血风险,难以在最低血小板计数与潜在不良事件之间建立明确联系。
  • 缺乏比较 ICU 预防性血小板输注不同血小板计数阈值的随机对照试验,预防策略主要源自血液科稳定患者研究。
  • 侵入操作前血小板输注阈值仍基于低级别证据。
  • 严重出血时血小板输注指征多为经验性,血小板计数阈值范围 50 至 100 × 109/L。
  • 严重创伤相关出血的大剂量输血方案包含早期积极血小板输注。

证据类型、等级与局限

  • 证据类型:叙述性综述。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,亟需针对重症患者的介入试验,以更好界定血小板输注的获益与危害。
  • ICU 预防性血小板输注阈值不宜直接照搬血液科稳定患者研究证据,因缺乏 ICU 随机对照试验。
  • 严重出血时血小板输注阈值 50 至 100 × 109/L 属经验性范围,侵入操作前阈值证据级别低。

指南或共识出处

  • Ann Intensive Care 发表的叙述性综述《Thrombocytopenia in the intensive care unit: diagnosis and management》。

提炼说明

  • 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: This narrative review aims to describe the epidemiology and aetiologies of thrombocytopenia in critically ill patients, the bleeding risk assessment in thrombocytopenic patients, and provide an update on platelet transfusion indications.

RESULTS: Thrombocytopenia is a common disorder in critically ill patients. The classic definition relies on an absolute platelet count below 150 × 109/L. Alternatively, the definition has extended to a relative decrease in platelet count (typically within a range of >30->50% decrease) from baseline, yet remaining above 150 × 109/L. Thrombocytopenia may result from multiple mechanisms depending upon the underlying conditions and the current clinical setting. Regardless of the causes, thrombocytopenia accounts as an independent determinant of poor outcomes in critically ill patients, albeit often of unclear interpretation. Nevertheless, it is well established that thrombocytopenia is associated with an increased incidence of bleeding complications. However, alternative factors also contribute to the risk of bleeding, making it difficult to establish definite links between nadir platelet counts at the expense of potential adverse events. Platelet transfusion represents the primary supportive treatment of thrombocytopenia to prevent or treat bleeding. As randomised controlled trials comparing different platelet count thresholds for prophylactic platelet transfusion in the ICU are lacking, the prophylactic transfusion strategy is largely derived from studies performed in stable haematology patients. Similarly, the platelet count transfusion threshold to secure invasive procedures remains based on a low level of evidence. Indications of platelet transfusions for the treatment of severe bleeding in thrombocytopenic patients remain largely empirical, with platelet count thresholds ranging from 50 to 100 × 109/L. In addition, early and aggressive platelet transfusion is part of massive transfusion protocols in the setting of severe trauma-related haemorrhage.

CONCLUSION: Thrombocytopenia in critically ill patients is very frequent with various etiologies, and is associated with worsened prognosis, with or without bleeding complications. Interventional trials focused on critically ill patients are eagerly needed to better delineate the benefits and harms of platelet transfusions.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Pène F, Russell L, Aubron C, et al. Thrombocytopenia in the intensive care unit: diagnosis and management. Ann Intensive Care. 2025. PMID: 39985745. doi:10.1186/s13613-025-01447-x

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。